Expression analysis of DUSP6, DAB2IP, and RKIP genes in patients with head and neck squamous cell carcinoma

Rezaei, Zahra; Shakoori, Abbas; Karimi, Ebrahim; Mokhtari, Zahra; Saffarzadeh, Negin; Nazari, T; Ahmadi, Mohsen; Bazzaz, Javad Tavakkoly

doi:10.1016/j.mgene.2020.100692

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In multiple solid tumors, DAB2IP is clearly downregulated and its expression levels negatively correlate with tumor growth, angiogenesis, lymph node metastasis, advanced clinical stage, and resistance to therapies, establishing it function as a tumor suppressor [5][6][7][8][9]. Although its relevance in tumor initiation remains undefined, available evidences strongly indicate that loss of DAB2IP represents an advantage for cancer progression and metastasis [1,2,10,11].…”

Section: Open Questionsmentioning

confidence: 99%

An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications

De Florian Fania,

Bellazzo,

Collavin

2024

Cell Death Differ

View full text Add to dashboard Cite

The dynamic crosstalk between tumor and stromal cells is a major determinant of cancer aggressiveness. The tumor-suppressor DAB2IP (Disabled homolog 2 interacting protein) plays an important role in this context, since it modulates cell responses to multiple extracellular inputs, including inflammatory cytokines and growth factors. DAB2IP is a RasGAP and negatively controls Ras-dependent mitogenic signals. In addition, it modulates other major oncogenic pathways, including TNFα/NF-κB, WNT/β-catenin, PI3K/AKT, and androgen receptor signaling. In line with its tumor-suppressive role, DAB2IP is frequently inactivated in cancer by transcriptional and post-transcriptional mechanisms, including promoter methylation, microRNA-mediated downregulation, and protein-protein interactions. Intriguingly, some observations suggest that downregulation of DAB2IP in cells of the tumor stroma could foster establishment of a pro-metastatic microenvironment. This review summarizes recent insights into the tumor-suppressive functions of DAB2IP and the consequences of its inactivation in cancer. In particular, we explore potential approaches aimed at reactivating DAB2IP, or augmenting its expression levels, as a novel strategy in cancer treatment. We suggest that reactivation or upregulation of DAB2IP would concurrently attenuate multiple oncogenic pathways in both cancer cells and the tumor microenvironment, with implications for improved treatment of a broad spectrum of tumors.

show abstract

Section: Open Questionsmentioning

confidence: 99%

An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications

De Florian Fania,

Bellazzo,

Collavin

2024

Cell Death Differ

View full text Add to dashboard Cite

show abstract

microRNA-1266-5p directly targets DAB2IP to enhance oncogenicity and metastasis in oral cancer

Peng

Lin

Chen

et al. 2022

Journal of Dental Sciences

View full text Add to dashboard Cite

Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target

Kambaru

Chaudhary

2022

CPB

View full text Add to dashboard Cite

: Protein Tyrosine Phosphatase (PTP) superfamily is a key enzyme involved in the regulation of growth-related cell signaling cascades, such as the RAS/MAPK pathway, that directly affect cancer cell growth and metastasis. Several studies have indicated that the drug resistance observed in several late-stage tumors might also be affected by the levels of PTP in the cell. Hence, these phosphatases have been in the limelight for the past few decades as potential drug-targets and several promising drug candidates have been developed, even though none of these drugs have reached the market yet. In this review, we explore the potential of PTP as a viable anti-cancer drug target by studying PTPs, their regulation of several key cancer cell signaling pathways and how their levels affect various types of cancer. Furthermore, we present the current scenario of PTP as a molecular target and the various challenges faced in the development of PTP-targeting anti-cancer drugs.

show abstract

Expression analysis of DUSP6, DAB2IP, and RKIP genes in patients with head and neck squamous cell carcinoma

Cited by 3 publications

References 26 publications

An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications

An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications

microRNA-1266-5p directly targets DAB2IP to enhance oncogenicity and metastasis in oral cancer

Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target

Contact Info

Product

Resources

About